Arbovirus Activation And Modulation Of NLRP3 Inflammasome
Funder
National Health and Medical Research Council
Funding Amount
$779,720.00
Summary
This project aims to establish how mosquito borne viruses such as Ross River and dengue viruses interacts with the human host to cause disease, including how the virus evades the host’s immune response to persist and cause disease for prolonged periods. Knowing how differences in the virus and the host’s immune system interplay to cause asymptomatic to severely disabling disease will assist in devising new treatments and prevention programs to lessen the impact of these diseases in Australia.
Mosquito-borne alphaviruses such as Ross River and chikungunya viruses cause widespread epidemics and exert extreme pressure on the public health systems of affected regions. Alphaviruses spreads to joints and triggers a severe disease in those affected. There are no effective treatments or vaccines. The project will investigate virus-host interaction at the bite site. The outcome will be new knowledge to treat infection at the mosquito bite site to prevent joint disease.
Novel Insights Into The Pathobiology Of Alphavirus Infections
Funder
National Health and Medical Research Council
Funding Amount
$827,660.00
Summary
Infections with mosquito-borne viruses are increasing at an alarming rate worldwide. Ross River virus is endemic in parts of Australia, PNG and Pacific islands, while chikungunya virus is distributed globally and causes recurrent pandemics that involve millions of people. These viruses cause severe musculoskeletal disease for several months after infection. This project aims to establish how these viruses interact with the human host to cause disease and may provide a basis for new treatments.
Glycotherapeutics; A New Class Of Treatment For Alphavirus-induced Musculoskeletal Disease
Funder
National Health and Medical Research Council
Funding Amount
$449,868.00
Summary
The hallmark of alphavirus disease is crippling pain and joint arthritis, which often has an extended duration. Currently there is no licenced specific treatment for alphavirus disease and the increasing spread of infection highlights an urgent need for therapeutic intervention strategies. This grant looks at the potential of pentosan polysulfate as a promising drug-repurposing candidate for the treatment of alphavirus-induced arthritis.
The Role Of Innate Inflammatory Responses In Viral Arthritis
Funder
National Health and Medical Research Council
Funding Amount
$782,514.00
Summary
Viruses are known to cause arthritis (HIV, hepatitis viruses, mosquito borne viruses). Symptoms of viral arthritis include joint pain, stiffness, and swelling. The mechanism of disease is poorly understood. We have developed a novel animal model of disease and human cell culture models by which to study disease caused by viral infections. This models provide an excellent opportunity to explore the mechanisms of rheumatic disease in a functioning animal and to explore new treatment regimes.
Inhibition Of Interferon-?/? Induction By Ross River Virus
Funder
National Health and Medical Research Council
Funding Amount
$589,664.00
Summary
Ross River virus is a mosquito-borne virus that causes arthritis in the joints of many people infected. This project will look at the early interactions of a virulent virus with the mammalian host that appear to enable the virus to replicate and spread in the host and thereby cause disease. These interactions are with the host interferon protein which the virus has developed the ability to inhibit. The effect of the invading virus on the host's interferon system, part of the immune system, will ....Ross River virus is a mosquito-borne virus that causes arthritis in the joints of many people infected. This project will look at the early interactions of a virulent virus with the mammalian host that appear to enable the virus to replicate and spread in the host and thereby cause disease. These interactions are with the host interferon protein which the virus has developed the ability to inhibit. The effect of the invading virus on the host's interferon system, part of the immune system, will be examined.Read moreRead less
A Pragmatic Randomised Clinical Trial Of Nicotine Vaporisers Added To Smoking Cessation Treatment For Priority Populations Living With Comorbidities
Funder
National Health and Medical Research Council
Funding Amount
$1,499,145.00
Summary
Smoking is a leading cause of early death for people with certain health conditions because they are more likely to smoke and are also at greater risk of tobacco-related disease. This clinical trial will test whether encouraging people living with Hepatitis C Virus, people on opiate substitution therapy and people living with HIV who smoke to use nicotine vaporisers long-term, in addition to current smoking cessation treatments, will help them to stay abstinent from smoking.
Novel Insights Into The Pathobiology Of Alphavirus Infections
Funder
National Health and Medical Research Council
Funding Amount
$583,477.00
Summary
Ross River virus and chikungunya virus cause muscle and joint pain that can persist for a long time. This project looks at factors in the human host that affect the disease severity, with the aim of finding new treatments.
A Cluster Randomised Controlled Trial Of Selective Decontamination Of The Digestive Tract In Critically Ill Patients
Funder
National Health and Medical Research Council
Funding Amount
$4,113,393.00
Summary
Sepsis is the most common cause of death in intensive care patients. Selective Decontamination of the Digestive Tract (SDD) is a treatment to reduce the risk of infection and improve survival for these patients. Many trials suggest SDD works but there has not been widespread uptake due to concerns that SDD will increase antibiotic resistance.rates. This trial will provide a definitive answer. If SDD reduces mortality without increasing antibiotic resistance, the study will have a global impact.
Use Of Molecular Resistance Assays To Provide Alterative Oral Treatment Strategies For Gonorrhoea In Indigenous And Other High-risk Populations; A Randomised Cluster Trial
Funder
National Health and Medical Research Council
Funding Amount
$828,671.00
Summary
Gonorrhoea has now developed resistance to almost all antibiotics that have been used to treat it. In this study, we will investigate a new treatment approach that selects antibiotics on a patient-by-patient basis. We will use new molecular assays to first test if a gonorrhoea strain infecting a patient is susceptible to an antibiotic, and will then treat on the basis of this result. By doing so, we will optimize our use of antibiotics and improve treatment strategies for gonorrhea.